News und Analysen

Pfizer (NYSE: PFE) has had its share of ups and downs in recent years. The pharma giant scored a major win in early pandemic days as it brought its coronavirus vaccine and later a coronavirus

CytomX Therapeutics (NASDAQ:CTMX), a biotech company that develops conditionally activated biologics for cancer treatment, closed Monday at $6.75, up 44.23%. The stock is jumping after releasing

Cormorant Asset Management disclosed a sale of 50,000 shares of Praxis Precision Medicines (NASDAQ:PRAX) in a February 17, 2026, SEC filing, with an estimated transaction value of $9.31 million

On February 17, 2026, ACT Capital Management disclosed a new position in Viking Therapeutics (NASDAQ:VKTX), acquiring 206,100 shares worth $7.25 million.

According to an SEC filing dated February

Close to 70 million seniors are covered by Medicare across the United States, according to the Centers for Medicare and Medicaid Services (CMS). Those covered seniors may soon find themselves

Part of the reason to own exchange-traded funds is to get exposure to all the investments you want. Contrary to what many investors believe, ETFs don't just cover stocks. You can find funds that

Vertex Pharmaceuticals (NASDAQ: VRTX) has had a busy few years. The biotech company, known for its leadership in the cystic fibrosis (CF) treatment market, has proven its ability to broaden into

The SPDR Gold ETF (NYSEMKT: GLD) broke new ground in the world of exchange-traded funds. Rather than just giving investors an ownership interest in shares of companies, SPDR Gold represented a way

According to a filing with the Securities and Exchange Commission dated Feb. 17, VR Adviser, LLC increased its position in Savara (NASDAQ:SVRA) by 1,059,332 shares during the fourth quarter. The

One nice thing about investing with exchange-traded funds is that you're not just limited to stock market investments. There are now ETFs available for a wide array of different asset classes

Over the past two years, Eli Lilly (NYSE: LLY) has established itself as the leader in the weight loss market. That's thanks to the company's tirzepatide, a compound sold under the brand name

Gregory T. Lucier, a member of the Board of Directors of Dentsply Sirona (NASDAQ:XRAY), reported the purchase of 15,000 shares of common stock at an average price of $12.45 per share on March 9

Vertex Pharmaceuticals (NASDAQ: VRTX) has encountered several clinical setbacks over the past 18 months, including for two products in its growing pain medicine franchise. Even with recent approvals

On February 17, 2026, Deerfield Management Company disclosed a buy of Praxis Precision Medicines (NASDAQ:PRAX), adding 62,500 shares in a trade estimated at $11.64 million based on quarterly average

On February 17, 2026, Driehaus Capital Management disclosed a buy of 432,510 shares of Praxis Precision Medicines (NASDAQ:PRAX), an estimated $80.54 million trade based on quarterly average pricing.

On February 17, 2026, Sphera Funds Management Ltd. disclosed a purchase of 374,847 shares of Syndax Pharmaceuticals (NASDAQ:SNDX), an estimated $6.54 million trade based on quarterly average

The wash-out from the COVID-19 pandemic has been brutal for any pharmaceutical stock. Pfizer (NYSE: PFE) has been no exception. As a vaccine maker, Pfizer has faced headwinds to growth in the last

Dividend investing is a proven way to grow your wealth over the long run. But for the strategy to work, investors need to pick quality income stocks, those with robust underlying businesses that are

A multibagger stock is one that has doubled your money or more. Peter Lynch, the highly respected investment manager who ran the Magellan Fund for 14 years, coined the term in his book, One Up on

On February 17, 2026, Orion Resource Partners disclosed in a U.S. Securities and Exchange Commission (SEC) filing that it sold out its position in Hudbay Minerals (NYSE:HBM), with an estimated

Frank P. Stewart, SVP, Advanced Cellular at Qorvo (NASDAQ:QRVO), reported the direct sale of 8,226 shares for a transaction value of approximately $683,000 on Feb. 17, 2026, according to a SEC Form

Shares in Vikinig Therapeutics (NASDAQ: VKTX) rose by 16.5% in February, according to data from S&P Global Market Intelligence. The move helped the stock recover in 2026, and at the time of writing,

In today's video, I discuss recent updates affecting Advanced Micro Devices (NASDAQ: AMD) and other AI stocks. To learn more, check out the short video, consider subscribing, and click the special

Some indicators suggest that equity markets are currently overvalued. For instance, the S&P 500 Shiller CAPE ratio is near multi-year highs. In this environment, it pays to look for bargains, stocks